Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05707754 · ClinicalTrials.gov registry record · Phase 1
Sphenopalatine Ganglion Block Study
A Phase 1 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
NCT05707754 is a Phase 1 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 220 participants.
The verdict
NCT05707754, a Phase 1 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to compare the administration and dosage of bupivacaine for sphenopalatine ganglion (SPG) nerve block. The main question\[s\] it aims to answer are: * Does a high dose (3ml) give more relief than a low dose (1ml)? * Does bilateral administration give more relief than unilateral? Participants with headaches will be asked to lie down and have SPG block performed. Researchers will compare dosage and administration to see how symptoms are reduced.
Interventions
- DRUG Bupivacaine
- DEVICE angiocatheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05707754
The ClinicalTrials.gov registry entry for NCT05707754 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT05707754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05707754 about?
NCT05707754 is a clinical study titled "Sphenopalatine Ganglion Block Study". The goal of this clinical trial is to compare the administration and dosage of bupivacaine for sphenopalatine ganglion (SPG) nerve block. The main question\[s\] it aims to answer are: * Does a high dose (3ml) give more relief than a low dose (1ml)? * Does bilateral administration give more relief t...
What is the current status of trial NCT05707754?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2023-03-06. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT05707754?
The interventions under investigation include: Bupivacaine (DRUG), angiocatheter (DEVICE).
Who is sponsoring clinical trial NCT05707754?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.